Comparing Harrow (NASDAQ:HROW) and Champions Oncology (NASDAQ:CSBR)

Harrow (NASDAQ:HROW) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Risk & Volatility

Harrow has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.

Profitability

This table compares Harrow and Champions Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Champions Oncology	-3.94%	-57.31%	-7.51%

Insider and Institutional Ownership

72.8% of Harrow shares are owned by institutional investors. Comparatively, 41.3% of Champions Oncology shares are owned by institutional investors. 12.8% of Harrow shares are owned by insiders. Comparatively, 47.0% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Harrow and Champions Oncology”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30 million	4.22	-$5.14 million	($0.41)	-75.27
Champions Oncology	$57.95 million	1.43	$4.70 million	($0.16)	-37.21

Champions Oncology has lower revenue, but higher earnings than Harrow. Harrow is trading at a lower price-to-earnings ratio than Champions Oncology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Harrow and Champions Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1	2	8	0	2.64
Champions Oncology	1	0	0	0	1.00

Harrow currently has a consensus price target of $69.43, indicating a potential upside of 124.98%. Given Harrow’s stronger consensus rating and higher possible upside, analysts clearly believe Harrow is more favorable than Champions Oncology.

Summary

Harrow beats Champions Oncology on 8 of the 14 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About Champions Oncology

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.